Research Focus

Former Employee. Medicine; Research Stdy Asst II

Recent additions – View all

1. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study

   Journal Article

   Scher, H. I.; Anand, A.; Rathkopf, D.; Shelkey, J.; Morris, M. J.; Danila, D. C.; Larson, S.; Humm, J.; Fleisher, M.; Sawyers, C. L.; more...
   Lancet (2010)

   Fulltext@MSK | Save
2. Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC)

   Meeting Abstract

   Scher, H. I.; Beer, T. M.; Higano, C. S.; Danila, D. C.; Montgomery, B.; Shelkey, J.; Hirmand, M.; Hung, D.; Sawyers, C.
   Journal of Clinical Oncology (2008)

   Fulltext@MSK | Save
3. Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials consortium

   Meeting Abstract

   Scher, H.; Beer, T.; Higano, C.; Logothetis, C.; Shelkey, J.; Hung, D.; Hirmand, M.; Larson, S.; Fleisher, M.; Sawyers, C.
   EJC Supplements (2008)

   Fulltext@MSK | Save